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Abstract
Background: Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate
classifications extracted from five different molecular levels in order to identify integrated subtypes.
Methods: Tumor tissue from 425 patients with primary breast cancer from the Oslo2 study was cut and blended, and
divided into fractions for DNA, RNA and protein isolation and metabolomics, allowing the acquisition of representative
and comparable molecular data. Patients were stratified into groups based on their tumor characteristics from five
different molecular levels, using various clustering methods. Finally, all previously identified and newly determined
subgroups were combined in a multilevel classification using a “cluster-of-clusters” approach with consensus clustering.
Results: Based on DNA copy number data, tumors were categorized into three groups according to the complex arm
aberration index. mRNA expression profiles divided tumors into five molecular subgroups according to PAM50
subtyping, and clustering based on microRNA expression revealed four subgroups. Reverse-phase protein array data
divided tumors into five subgroups. Hierarchical clustering of tumor metabolic profiles revealed three clusters.
Combining DNA copy number and mRNA expression classified tumors into seven clusters based on pathway activity
levels, and tumors were classified into ten subtypes using integrative clustering. The final consensus clustering that
incorporated all aforementioned subtypes revealed six major groups. Five corresponded well with the mRNA subtypes,
while a sixth group resulted from a split of the luminal A subtype; these tumors belonged to distinct microRNA
clusters. Gain-of-function studies using MCF-7 cells showed that microRNAs differentially expressed between the
luminal A clusters were important for cancer cell survival. These microRNAs were used to validate the split in luminal A
tumors in four independent breast cancer cohorts. In two cohorts the microRNAs divided tumors into subgroups with
significantly different outcomes, and in another a trend was observed.
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Conclusions: The six integrated subtypes identified confirm the heterogeneity of breast cancer and show
that finer subdivisions of subtypes are evident. Increasing knowledge of the heterogeneity of the luminal A
subtype may add pivotal information to guide therapeutic choices, evidently bringing us closer to improved
treatment for this largest subgroup of breast cancer.
Keywords: Breast cancer, Integration, Luminal A, Consensus clustering, MicroRNA
Background
Breast cancer is a disease that has been thoroughly pro-
filed on various levels revealing heterogeneity that is
manifest at the clinical, histopathological and molecular
level. At each level, separation of breast tumors into dif-
ferent groups has been used to identify subgroups of the
disease, which assists patient management. The two
major groups of breast cancer at the histopathological
level are the estrogen receptor (ER)-positive and ER-
negative tumors, encompassing all other molecular sub-
groups. Further, at the gene expression level, five main
subgroups have been identified [1, 2], and combining
gene expression with copy number data further refined
breast cancer into 10 integrated subgroups with different
genomic and transcriptomic profiles and prognosis [3].
Recently, mutation data coupled to these 10 subgroups
showed how functional mutations in the PIK3CA gene
were associated with different survival times in ER-
positive breast cancer when stratifying by these inte-
grated subgroups [4]. Integrating classifications extracted
from four different levels (mRNA, microRNA (miRNA)
expression, DNA copy number and methylation) re-
vealed new insights into the biology and immune profile
of pre-invasive and invasive breast cancers [5], while
metabolic analyses have revealed three naturally occur-
ring clusters with distinct metabolic profiles [6]. Explor-
ing the causes and consequences of breast cancer at a
higher level may lead to refined therapeutic strategies.
Tumor development and progression is a dynamic
evolutionary process involving genomic and epigenetic
aberrations, cellular context, influence from the sur-
rounding environment and patient-specific character-
istics. Furthermore, cancer is increasingly being
understood as a disease with alterations at the net-
work level where multiple different changes can en-
gender a similar cancer phenotype or outcome [7].
Integration of molecular data is needed to uncover
these alterations in single tumors and further link
them across patients to understand the effects on net-
work levels. Also, integrative analyses may generate
explanatory power that one data type alone cannot
provide [8]. The long-term goal of this approach is
further stratification of patients into subgroups for
improved tailored therapy. The information content
in integrated analyses is higher than in any of the
separate molecular-level studies; however, the avail-
ability of all these layers of data from the same
patients is often limited.
Using data from five molecular platforms (mRNA ex-
pression, protein expression, miRNA expression, DNA
copy number and methylation), The Cancer Genome
Atlas (TCGA) performed a multiplatform integrative
analysis on 348 breast tumors [9]. The subtypes (clus-
ters) defined from each of the molecular levels were sub-
jected to unsupervised consensus clustering revealing
four major patient groups. These “higher-order” sub-
types corresponded well with the mRNA expression-
defined PAM50 subtypes and as such did not identify
new subgroups within the subtypes. The same cluster-
of-clusters approach was also applied to the correspond-
ing molecular data from 12 different cancer types [10],
revealing 11 major subtypes. Interestingly, although
most of the multiplatform subtypes correlated with tis-
sue of origin, some of the tumor types coalesced into
one subtype, while, for example, breast cancer was split
into two subtypes and bladder cancer into three different
subtypes [10].
The Oslo2 study is a multicenter study initiated in
2006, in which patients with breast cancer were enrolled
from Oslo University Hospital. So far, 2000 patients have
been enrolled into the study, and here we present an
analysis of the first 355 patients in addition to 70
patients from a similar study performed at Akershus
University Hospital. In this study, we integrated seven
different classifications extracted from five molecular
levels; DNA copy number, mRNA, miRNA and protein
expression and tumor metabolic profiles. The aim was
to identify higher-order integrated subtypes. Whenever
possible, we used existing clustering schemes, as devel-
oped and tested in the literature, including the cluster-
of-clusters analysis (COCA) methods previously
described [9, 10]. In this way we provided comparable
evidence on how the population-based Oslo2 cohort
represents the previously described subtypes and on
how these compare to newly identified subtypes.
Methods
The Oslo2 clinical cohort
Oslo2 is a multicenter study in which patients with
primary operable breast cancer (cancer tumor stage
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(cT)1–cT2) were consecutively enrolled at Oslo University
Hospital, Norway (including the Radium Hospital and
Ullevål Hospital, Vestre Viken and Østfold Hospital in
southeast Norway). Patients were included from 2006, at
the time of primary surgery after giving written informed
consent. Here we present an analysis of the first subset of
355 patients. The Regional Committee for Medical and
Health Research Ethics for southeast Norway has ap-
proved the study (approval number 1.2006.1607 and
1.2007.1125, 2009/615, 2009/4935).
Experienced breast pathologists macroscopically evalu-
ated the surgical specimens before parts of the tumor
were fresh frozen (-80 °C). Patients were followed ac-
cording to national guidelines for follow up after breast
cancer treatment. A fresh-frozen biopsy sample from the
primary tumor and peripheral blood samples were col-
lected at the time of surgery. In addition, bone marrow
and lymph nodes were collected. Tumor tissue and
blood specimens were collected from patients who expe-
rienced relapse.
Samples from the Oslo2 study were coupled with
tumor tissue collected from 70 patients from a similar
study conducted at the Akershus University Hospital,
Norway (approval number 429-04148) from 2003 to
2010. In total, tumor tissue from 425 patients was used
in the current analyses and the patient cohort is collect-
ively described as the Oslo2 cohort.
Clinical data
Clinical parameters were collected from patient records
and from pathology reports. Hormone receptor status
for estrogen receptor (ER) and progesterone receptor
(PR) were obtained by standard immunohistochemical
assessment (IHC). Amplification of the human epider-
mal growth factor receptor 2 (HER2) gene was assessed
by a combination of IHC and chromogenic in situ
hybridization (CISH) following standard guidelines.
Experienced pathologists assessed tumor size, morph-
ology, histological grade and axillary lymph node
involvement as part of standard diagnostic routine. Age,
mode of detection, surgical procedure and presence of
metastatic disease at the time of diagnosis were collected
from hospital records. Following national guidelines for
breast cancer, screening for metastases is not standard
procedure in asymptomatic patients at diagnosis. Thus,
most patients did not undergo magnetic resonance
imaging (MRI) or computed tomography (CT) to detect
metastases.
Tumor preparation
Biopsies from Oslo University Hospital were taken at
the time of surgery and fresh-frozen. The tumor was
cut into three pieces. Frozen sections were taken
from the flanking pieces facing the middle piece,
stained with hematoxylin and eosin and evaluated by
a pathologist for the presence of tumor cell percent-
age. The average tumor cell percentage was 53%
(range 0–90%). A tumor tissue sample from the mid-
dle piece was taken for high-resolution magic-angle
spinning magnetic resonance spectroscopy (HR MAS
MRS). Following this, the three tumor pieces were
merged, cut into smaller pieces by scalpel, mixed and
split into dedicated vials for DNA, RNA and protein
isolation. Biopsies from Akershus University Hospital
were first put on RNAlater (Thermo Fisher scientific,
Waltham, MA, USA) overnight before being frozen at
-80 °C. The preparation was performed as described
previously, but without dedicated vials for HR MAS
MRS and protein isolation.
DNA and RNA isolation
DNA isolation was performed using the Maxwell® 16 in-
strument (Promega, Fitchburg, WI, USA) and the Max-
well® 16 tissue DNA Purification Kit (Promega). DNA
was isolated according to the manufacturer’s protocol. In
brief, tumor tissue was transferred into the Maxwell
cartridge cassettes predispensed with magnetic beads,
lysis buffer, and wash buffers of isopropanol and ethanol.
The isolation procedure is automated, starting with sam-
ple lysis and tissue homogenization, following bead iso-
lation of DNA, and finally washing steps. The DNA was
eluted in 200–600 ul TE-buffer (pH 8.5). DNA was
stored at -20 °C.
Total RNA was isolated by phenol-chloroform extrac-
tion using the TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s instructions and has
been described previously [11]. The NanoDrop spectro-
photometer (Thermo Fisher scientific) was used to as-
sess the concentration and RNA purity by measuring
absorbance at different wavelengths. The quality and in-
tegrity of the RNA was assessed by chip‐based capillary
electrophoresis using a 2100 Bioanalyzer instrument
(Agilent Technologies, Santa Clara, CA, USA). The
resulting average RNA integrity number (RIN) of all
samples was 5.6, range 1.0–9.7.
TP53 sequencing
TP53 mutation analysis of exon 2-11 was performed
by Sanger sequencing using the 3730 DNA Analyzer
(Applied Biosystems, Life Technologies Corporation,
Carlsbad, CA, USA). PCR amplification with the
BigDye Direct Cycle Sequencing Kit (Applied Biosys-
tems) was performed using 5 ng tumor DNA,
followed by BigDye XTerminator Purification Kit
(Applied Biosystems). The sequences were read in
SeqScape v.2.7 (Applied Biosystems) by two independ-
ent investigators.
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PIK3CA mutation detection
Mutations in the PIK3CA gene were detected using a mass
spectroscopy-based approach in addition to Sanger se-
quencing. In total, 314 tumors were evaluated for ten
known PIK3CA mutations using the Sequenom MassArray
MALDI-TOF MassArray system (Sequenom, San Diego,
CA, USA) as previously described [12]: PIK3CA_C42
0R_T1258C, PIK3CA_E110K_G328A, PIK3CA_E542KQ_
G1624AC PIK3CA_E545KQ_G1633AC, PIK3CA_G1049
R_G3145C, PIK3CA_H1047RL_A3140GT PIK3CA_K11
1N_G333C, PIK3CA_N345K_T1035A, PIK3CA_P539R_
C1616G and PIK3CA_Q546LPR_A1637TCG.
A subset of the tumor samples (n = 275) were se-
quenced for detection of mutations in PIK3CA exon 9
and 20. PCR touchdown reaction with HotStarTaq DNA
polymerase (Qiagen, Hilden, Germany) was performed
using 10 ng of DNA. The PCR products were visualized
on a 1.5% agarose gel, and the products were cleaned
with EpMotion 5075 (Eppendorf AG, Hamburg,
Germany). For the sequencing reactions, 3 ul of the
purified PCR product and BigDye Terminator v1.1 reac-
tion mix was used. Sequencing reactions were performed
on MJ Research Tetrad DNA Engine (MJ Research, Bio-
Rad Laboratories Inc., Hercules, CA, USA), and cleaned
on Sephadex mini-columns (GE Healthcare Life Sci-
ences, Little Chalfont, UK). Sequencing was performed
using a 3730 DNA Analyzer (Applied Biosystems).
Mutation scoring was performed in SeqScape v.2.7
(Applied Biosystems) by two independent investigators.
For tumor samples evaluated by both approaches, the
results were combined by identifying a tumor sample as
PIK3CA-mutated if at least one of the methods detected
a mutation.
Copy number aberration analysis, segmentation and
complex arm aberration index
Tumor DNA was hybridized to Affymetrix SNP 6.0
arrays (Affymetrix, Santa Clara, CA, USA) at Aros
Applied Biotechnology (Aarhus, Denmark) following the
manufacturer’s recommendations. Tumor samples col-
lected at the Akershus University Hospital were stored
on RNAlater. DNA extracted from a majority of these
samples did not pass the quality control assessment for
single nucleotide polymorphism (SNP) arrays. Affyme-
trix CEL-files were processed using the PennCNV-Affy
library [13], with the HapMap samples as the reference
set [14]. Correction for GC-related binding bias was
performed [15]. The resulting GC-adjusted LogRs were
segmented into regions of constant copy number using
the R package “copynumber” [16] in the Comprehensive
R Archive Network (CRAN) [17]. The complex arm
aberration index (CAAI) was computed as described
previously [18]. Note that in the original paper CAAI-
values were thresholded only at the value 0.5 to produce
a dichotomous variable, but here we also distinguished
between the number of arms with a CAAI event; zero
arms, one arm or at least two arms.
Gene expression and PAM50 subtypes
mRNA expression was measured using SurePrint G3
Human GE 8x60K one-color microarrays from Agilent
(Agilent Technologies) according to the manufacturer’s
protocol and using 100 ng of RNA as input for amplifi-
cation. The array includes 42,405 unique 60-mer probes,
targeting 27,958 Entrez genes and 7419 long intergenic
non-coding RNAs (lincRNAs). Scanning was performed
with Agilent Scanner G2565A, and signals were ex-
tracted using Feature Extraction v.10.7.3.1 (Agilent
Technologies). Non-uniform spots were excluded and
missing data were imputed using local least squares
imputation (LLSimpute from the R package “pcaMethods”
[19]). Arrays were log2-transformed, quantile-normalized
and hospital-adjusted by subtracting from each probe
value the mean probe value of the samples from that
same hospital. To have a single expression value per
gene per sample, the values corresponding to probes
with identical Entrez ID were averaged. A cutoff was
applied on the RIN value to exclude samples with an
RIN value below 2.5. mRNA expression data have
been submitted to the Gene Expression Omnibus
(GEO) database [GEO:GSE80999].
The PAM50 subtype algorithm [20] was used to as-
sign a gene expression subtype label to each sample.
For each sample, a 50-dimensional vector was found
by extracting the gene expression values for the 50
genes in the PAM50 gene list. A 50-dimensional
centroid vector was then calculated by averaging the
gene expression vectors for all the ER-positive sam-
ples, and likewise a 50-dimensional centroid vector
was calculated by averaging the gene expression
vectors for all the ER-negative samples. A combined
centroid was then defined as a weighted average of
the ER-negative and the ER-positive centroids, the
weights being c and 1-c, where c is the proportion of
ER-negative samples in the original dataset (the train-
ing data set) used in Parker et al. [20] to define the
PAM50 centroids. The samples to be subtyped were
then centered by aligning the combined centroid with
the centroid of the training dataset. This was achieved
by subtracting from the expression vector of each
sample the combined centroid and then adding the
centroid of the training dataset. Finally, one of the
subtype labels luminal A, luminal B, basal, normal-
like or HER2 was assigned to each sample by calcu-
lating the Spearman correlation between the centered
expression vector of the sample and each of the five
PAM50 centroids, and selecting the one with the
strongest correlation.
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Protein expression and subtypes
Protein levels were determined using reverse phase pro-
tein array (RPPA), a platform whereby single protein
levels can be measured across a series of samples simul-
taneously [21]. Altogether 148 primary antibodies were
used to detect cancer-related proteins. Frozen tumor
samples from patients with sufficient material (from
Oslo University Hospital) were lysed by homogenization
in lysis buffer containing proteinase inhibitors and phos-
phatase inhibitors. The tumor lysates were diluted to
1.33 mg/ml concentration as assessed by bicinchonic
acid assay and boiled in 1% SDS and 2-mercaptoethanol.
Supernatants were manually diluted in five serial two-
fold dilutions with lysis buffer. The samples were spotted
onto and immobilized on nitrocellulose-coated FAST
slides. The slides were probed with 105 primary highly
validated antibodies in the appropriate dilution. The sig-
nal intensity was captured by a biotin-conjugated sec-
ondary antibody and was amplified using the
DakoCytomation-catalyzed system (Dako, Glostrup,
Denmark). Slides were scanned, analyzed and quanti-
tated using MicroVigene software (VigeneTech Inc.,
Carlise, MA, USA) to generate spot signal intensities.
These were then processed by the R package “Super-
Curve” (version 1.01), available at http://bioinformatics.m
danderson.org/OOMPA [22]. The protein concentrations
were derived from the supercurve for each sample by
curve fitting, log2-transformed, and the relative concentra-
tions were normalized by median centering of the samples
for each of the antibodies.
RPPA subtypes were obtained using non-negative
matrix factorization as done in [9]. Consensus clustering
of the samples was performed with an option for four
or five groups using Pearson correlation coefficient-
based distance and Ward’s minimum variance-based
agglomeration method. The best fit on consensus
clustering identified five groups: luminal, HER2, basal
and reactive I and reactive II, as defined in the TCGA
dataset [9]. The RPPA data can be found in Additional
file 1a (parts of the data (i.e. total protein antibodies)
have been published previously [11]).
miRNA expression and clusters
miRNA expression was measured using the one-color
microarray Human miRNA Microarray Kit (V2) design
ID 029297 (Agilent Technologies) according to the
protocol supplied by the manufacturer (miRNA Micro-
array System v2.3). This array contains 887 human miR-
NAs and is based on miRBase release 14.0. Each array is
spotted by 14,907 features (60-mers) including 715 con-
trol probes; hence each miRNA is on average replicated
approximately 16 times. For labeling and hybridization
to the array, 100 ng total RNA was used as input. Scan-
ning was performed on the Agilent Scanner G2565A.
Samples were processed using Feature Extraction version
10.7.3.1 (Agilent Technologies). All except two tumors
that did not pass array quality control were included in
downstream analysis. The data were log2-transformed
and centered on the 90th percentile using GeneSpring
GX v.11.0 (Agilent Technologies). In total, 421 miRNAs
were considered to be expressed in the Oslo2 cohort,
after filtering out miRNAs detected in fewer than 10% of
samples. The miRNA expression data have been submit-
ted to the GEO database [GEO:GSE81000].
In order to identify patient clusters based on miRNA
expression, the partitioning algorithm using recursive
thresholding (PART) method available in the R package
“clusterGenomics” [23] was used. The PART method de-
termines the number of clusters by recursive partitioning
of the samples into subgroups. This means that it first
attempts to split the data into an optimal number of
subgroups by a flat cut of the dendrogram. It then ap-
plies the same procedure to each of the clusters identi-
fied, to see if any of these can be further split into
subgroups. The benefit of this method is that it allows
the dendrogram to be split into clusters occurring at dif-
ferent heights in the dendrogram, thus circumventing
the limitation of using only flat cuts of the dendrogram
to define clusters. The parameter Kmax is a technical
parameter defining the maximum number of clusters to
be identified at each stage of this procedure. PART was
applied with the Pearson correlation coefficient based-
distance and complete linkage and parameters Kmax = 4,
minSize = 41 and B = 1000.
Metabolic spectra and clusters
Tumor samples from the Oslo University Hospital of
sufficient size to obtain a biopsy sample for high-
resolution magic-angle spinning magnetic resonance
spectroscopy (HR MAS MRS) were cut to fit into 30-μl
inserts containing 3.0 μl of 24.29 mM sodium formate
(VWR BDH Prolabo, France) in D2O (Armar Chemicals,
Switzerland). Each insert was set tightly into a 4 mm op-
tical density (o.d.) MAS zirconium rotor. Samples
weighed 7.26 mg on average (2.10–15.60 mg). HR MAS
MRS spectra were acquired on a BrukerAvance DRX600
spectrometer equipped with a 1H/13C MAS probe (Bru-
ker, BioSpin GmbH, Germany). Samples were spun at
5 kHz while kept at a temperature of 5 °C to minimize
degradation. A spin-echo one-dimensional experiment
with presaturation (cpmgpr1d, Bruker, BioSpin GmbH,
Germany) was performed on all samples.
The spectral region between 1.40 and 4.70 parts per
million (ppm) containing the major information from
low molecular metabolites, excluding lipid-containing
regions at 4.36-4.27, 2.88–2.70, 2.30–2.20, 2.09–1.93 and
1.67–1.50, was mean normalized and used for unsuper-
vised hierarchical cluster analysis using the Euclidean
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distance and Ward’s minimum variance-based agglomer-
ation method (Statistical toolbox, Matlab R2013b, The
Mathworks, Inc., USA). The dendrogram was cut to give
three metabolic clusters (1–3). Relative intensities from in-
tegration of spectral regions were used to measure metab-
olite levels [6]. The clusters were tested for differences in
expression using the Kruskal-Wallis test and corrected for
multiple testing with the Benjamini-Hochberg false
discovery rate (FDR) [24]. The metabolic data and cluster
assignments have been published previously [25].
Classification of the Oslo2 samples in the ten integrative
clusters
Samples in the Oslo2 cohort were assigned to the ten in-
tegrative clusters (IntClust) identified in the Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC) cohort [3] using integrative clustering
(iClustering) [26]. With this aim, the same pipeline as
used by Curtis et al. [3] was employed: the pipeline as-
signs the METABRIC samples in the validation set to
the ten clusters obtained from the discovery set. The
METABRIC cohort includes 1980 patients (997 in the
discovery set, and 983 in the validation set). Integrative
clustering is used on the discovery set in order to esti-
mate cluster centroids and the most relevant features
(genes) for clustering. METABRIC finally selects ten
clusters based on 754 features (39 are segmented copy
number aberrations (CNAs) and 715 gene expressions).
For assigning the Oslo2 data to these ten clusters, we
used the Oslo2 samples for which both CNAs and gene
expressions were available (n = 291). We also used the
same 754 features as in the METABRIC case. As the
platforms were different, in order to make the gene ex-
pressions and CNAs of the Oslo2 cohort comparable to
the METABRIC ones, the Oslo2 data were normalized
to have the same mean and standard deviation as the
METABRIC data.
In the analysis of Curtis et al. [3] the assignment of
the samples in the validation set to the clusters obtained
from the discovery set was performed using nearest
shrunken centroid (NSC; see [27]), a supervised classifi-
cation method where cluster centroids are also
shrunken. NSC has two phases: in the training phase,
ten new shrunken centroids were estimated starting
from the original centroids (given in [3]), using the
within-cluster standard deviation of each of the 754 fea-
tures. In the testing phase, each selected Oslo2 sample
was assigned to one of the ten shrunken centroids, thus
identifying cluster membership.
Pathway recognition algorithm using data integration on
genomic models
The pathway recognition algorithm using data integra-
tion on genomic models (PARADIGM) infers distinct
biological pathway activity from multiple genomic data
(here, mRNA expression and copy number) in a patient
sample [5, 28]. The pathway concepts (genes, complexes
and abstract processes) are derived from the Pathway
Interaction Database [29], BioCarta (http://cgap.nci.nih.
gov/Pathways/BioCarta_Pathways), and Reactome data-
bases [30]. Copy number is estimated from AROMA
CRMA v2 followed by circular binary segmentation
(non-paired CBS) to gene level measurement [31, 32].
The normalized mRNA expression and the 25% most
variable copy number data were used for calculating
inferred pathway levels (IPL) at five3genomics.com.
Clustering was performed by HOPACH 2.10 [33] in R
version 3.0.0 [17] and visualized using cluster 3.0 [34]
and Java TreeView ver.1.1.6r3 [35]. For the HOPACH
hierarchical clustering algorithm, we used correlation
distance “cor” and clustering criteria function “med”
(median split silhouette) in the mss parameter (mss
determines the number of children at each node, to
decide what collapsing should be performed at each
level, and to determine the main clusters).
Consensus clustering across the multiple classifications
Consensus Clustering [36] is a method to represent the
consensus across multiple classifications. We used the R
package “ConsensusClusterPlus” [37] to estimate a final
clustering of the Oslo2 cohort starting from multiple
classifications. Only the samples that were clustered with
at least two methods were included in the consensus
clustering analysis. Consensus clustering was run using
hierarchical clustering with normalized Manhattan dis-
tance and Ward linkage, and the final choice resulted in
six clusters. The number of COCA clusters was selected
by inspecting the average silhouette value [38] associated
to the final grouping, which showed a global maximum
when selecting six consensus clusters. The clusters selec-
tion criterion suggested by the authors proposing the
COCA method [36] was also examined to support this
choice.
Association of COCA clusters to clinical parameters and
correlation to molecular subtype levels
To associate the identified COCA clusters to clinical
parameters, a Chi-squared association test was used. To
assess the correlation between COCA clusters and
molecular subtype levels the Pearson correlation coeffi-
cient was calculated. This was done by first coding each
sample 0/1 if it belonged (or not) to each molecular
subtype and each COCA cluster and then correlating a
given 0/1 COCA cluster vector with a given 0/1 molecu-
lar subtype vector.
Additional file 2a contains further methodological
description. All computational analyses were performed
in R [17] unless otherwise specified.
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Results
Samples and clinical data
This collection of 425 primary breast tumors represents
a consecutive breast cancer cohort. For each molecular
level, different numbers of patients were classified (in
descending order): miRNA expression (n = 423), PAM50
gene expression (n = 377), complex arm aberration index
(CAAI) (n = 349), PARADIGM (n = 312), IntClust (n =
291), metabolic profiling (n = 233) and RPPA (n = 173).
Altogether 80 patients had available data from all seven
levels. The various molecular levels are further described
subsequently. An overview of the clinicopathological
data on the patients is provided in Additional file 2b and
the tumor sample classifications are listed in Additional
file 1b.
PAM50 gene expression subtypes
Tumor samples with mRNA expression data available
were classified into gene expression-based subtypes
based on the PAM50 model [20] (Fig. 1a). PAM50 sub-
typing classifies breast tumors into one of five subtypes
on the basis of the measured expression of 50 selected
genes. It compares the tumor gene-expression vector
with five centroids that represent the subtypes. The
nearest centroid is identified, and the corresponding
subtype label is assigned to the tumor. Among the
tumors with available mRNA expression data the major-
ity of samples were classified as luminal samples, com-
prising 41.6% luminal A and 23.6% luminal B samples.
The remaining samples were classified as basal (12.0%),
HER2-enriched (11.1%) and normal-like (11.7%).
Classification based on protein expression
The RPPA subtypes are based on clustering the expres-
sion levels of 148 selected cancer-associated proteins
(Additional file 1a). The five RPPA subtypes found in the
Oslo2 dataset have been previously defined [9]. There
was strong concordance between three of these - basal,
HER2 and in part, the luminal subtype - and the corre-
sponding gene expression-based PAM50 subtypes
(Fig. 1b). The remaining two subtypes, reactive I and
reactive II, originally had protein expression profiles
characteristic of the microenvironment and/or cancer-
activated fibroblast [9] and have recently been shown
to represent a high stromal content in the context of a
highly differentiated tumor [39]. Here, they overlapped
mostly with the luminal A and normal-like PAM50
subtypes.
CAAI scoring from CNA data
The CAAI index identifies complex architectural alter-
ations on chromosome arms, which are characterized by
physically tight clusters of breakpoints with large
changes in amplitude [18]. Identification of CAAI events
is a measure of the local distortion on chromosome
arms and has previously been shown to be an inde-
pendent prognostic marker [18, 40]. Among the 349
tumors with available CAAI scores, 35.5% had no
CAAI event (CAAI <0.5 for all arms), 24.7% had one
CAAI event (one chromosome arm with CAAI ≥ 0.5),
and 39.8% had at least two CAAI events (Fig. 1c).
The three CAAI groups all have representatives from
each of the PAM50 subtypes. As expected, HER2-
positive tumors were classified as CAAI 1 or CAAI 2
as they often have amplification of the 17q region
harboring the ERBB2 gene [41].
miRNA expression classification
By applying the PART algorithm [23] to separate the
tumor samples into clusters based on miRNA expres-
sion, we identified four clusters (Fig. 1d and Additional
file 3). Tumors of the luminal expression subtypes
(luminal A and B) were mostly found in cluster 1 and 2,
while basal-like tumors were mainly found in cluster 3,
which was dominated by ER-/PR-negative tumors.
HER2-positive tumors were not clustered together;
rather they were distributed across the clusters 1, 2
and 3 (Additional file 3). miRNA cluster 4 was a mix-
ture of mostly normal-like and luminal samples; how-
ever, a subset of tumors in this cluster did not have
PAM50 expression subtype classification due to lack
of available mRNA expression data. miRNAs that
were differentially expressed between the clusters are
listed in Additional file 4.
Classification of tumors based on metabolic profiles
HR MAS MRS was performed on 233 breast tumors
in order to extract tumor metabolic profiles [6].
Unsupervised hierarchical clustering analysis separated
the tumors into three metabolic clusters (Fig. 1e; [6]).
The clusters differed in the expression of metabolites
involved in phospholipid metabolism, glycolytic activ-
ity and glutaminolysis. Cluster 1 tumors had the high-
est levels of the choline-containing metabolites
glycerophosphocholine (GPC) and phosphocholine
(PCho). Altered choline metabolism is an emerging
hallmark of malignant transformation [42] and both
GPC and PCho have previously been confirmed to be
elevated in tumor tissue compared to non-involved
breast tumor tissue [43]. Cluster 1 tumors also had
evidence of increased glycolytic activity, with low
levels of glucose and high levels of lactate ap-
proaching statistical significance when compared to
cluster 2 tumors. However, cluster 3 tumors had a
more apparent glycolytic switch, with the highest
levels of lactate among all three clusters, combined
with high alanine and low glucose levels. Cluster 2
tumors expressed significantly higher levels of glucose
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and lower levels of lactate and alanine, indicative of lower
glucose consumption and glycolytic activity. Increased
glucose consumption has been shown to correlate with
poor prognosis and tumor aggressiveness [44], inferring
that patients with cluster 2 tumors have a better prognosis
than patients with cluster 1 or cluster 3 tumors. There
was no correlation between the three metabolic clusters
and PAM50 subtypes.
Integrated clusters
iClustering [26] is a sparse clustering method originally
used to perform breast tumor subtyping in the METAB-
RIC cohort [3]. The subtyping is based on 754 selected
features (715 gene expression and 39 copy number
values). Among the samples in the Oslo2 cohort, data
from 291 tumors were selected according to the avail-
ability of gene expression and copy number data, and
Fig. 1 The seven input levels for integrative clustering and association with clinical/molecular classifications. Original subtypes/clusters of each
input level and corresponding PAM50 gene expression subtype, estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor
receptor 2 (HER2) status, and TP53 and PIK3CA mutation status of the tumor samples. The tumor samples are sorted in the following order:
molecular level, PAM50 gene expression subtype, ER, PR, HER2, TP53 and PIK3CA status. a PAM50 gene expression subtypes (n = 377). b Reverse-phase
protein array (RPPA) subtypes (n = 173). c Complex arm aberration index (CAAI) subtypes (n = 349). 0 no CAAI events, 1 one CAAI event, 2 at least two
CAAI events. d miRNA clusters (n = 423). e Metabolic clusters (n = 233). f Integrated clusters (IntClust; n = 291). g Pathway recognition algorithm
using data integration on genomic models (PARADIGM) clusters (n = 312). Lum luminal, Pos positive, Neg negative, Mut mutant, Wt wild-type,
NA not applicable
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they were assigned to the 10 IntClusts identified in the
METABRIC cohort. The IntClust assignments and clin-
ical annotations of these samples are shown in Fig. 1f.
The assignment to IntClust centroids resulted in 22
samples being assigned to IntClust 1, 13 to IntClust 2,
57 to IntClust 3, 51 to IntClust 4, 27 to IntClust 5, 18 to
IntClust 6, 19 to IntClust 7, 37 to IntClust 8, 21 to
IntClust 9 and 26 to IntClust 10. The distribution into
IntClusts was similar to that in the METABRIC cohort.
Some of the IntClusts correlated with the PAM50 sub-
types, for example IntClust 3 and 5 were mainly com-
posed of luminal A and HER2-enriched tumors,
respectively, while IntClust 10 consisted entirely of
basal-like tumors.
Patient clusters based on pathway activity levels
The PARADIGM algorithm infers patient-specific
pathway activity by incorporating gene expression and
copy number data with pathway information [28].
Clustering the inferred pathway activities resulted in
identification of seven patient clusters of varying size
(Fig. 1g). IPLs for the top deregulated pathway
entities across the clusters are visualized as a heatmap
in Additional file 5. The pathways with levels that
most strongly contributed to these groups were those
related to transcription factors such as ER, E2F1,
Myb, Myc/Max, Jun/Fos and TP53. A list of the top
500 pathway entities defining the seven clusters is
supplied in Additional file 6.
Multilevel classification using consensus clustering
COCA is a clustering method whereby cluster assign-
ments found on multiple data levels are jointly used for
subtype classification. It was first applied on TCGA
breast cancer data [9] and then later on a TCGA pan-
cancer study [10]. The purpose of using this method is
to explore the higher-order composition of tumors,
which might not be visible when considering one data
level at a time, and to see how multiple molecular levels
are associated when integrated. In this study, single-level
classifications based on gene/protein/miRNA expression,
CNAs and metabolic profiles were clustered together
with classifications based on the combined analysis of
copy number and gene expression using iClustering and
PARADIGM. Unsupervised consensus clustering of
seven levels of classifications of the Oslo2 data (n = 419
tumors with at least two data levels available) revealed
six clusters of varying size (Fig. 2). The tumor sample
classifications to COCA clusters are listed in Additional
file 1b.
In order to investigate the association between the
various molecular subtype levels and COCA clusters, the
Pearson correlation coefficient between each molecular
subtype level and each COCA cluster was calculated.
This was done by coding each sample 0/1 if it belonged
(or not) to each molecular subtype and each COCA
cluster (Table 1 and Additional file 1c). Interestingly,
miRNA clusters and PAM50 subtypes were the levels
that were most frequently strongly correlated with the
COCA clusters (Table 1). For the COCA cluster 3
(basal) and COCA cluster 6 (HER2) there was strong
correlation to more levels than for the other clusters.
This suggests that the luminal clusters can be further
subdivided by the COCA clustering approach using data
from multiple platforms.
COCA cluster 1
COCA cluster 1 was the largest in size (n = 141) and
tumors of cluster 1 were most strongly correlated with
miRNA cluster 2 (r = 0.80), with 125 (88.7%) of the
tumors in cluster 1 assigned to this miRNA cluster.
Interestingly, as more than half of the tumors in cluster
1 were classified as luminal A samples (n = 75; 53.2%)
and all other luminal A samples (n = 82) except two
were found in cluster 4, this revealed a split in the
luminal A tumors. Although this cluster was dominated
by luminal A tumors, cluster 1 was the most mixed clus-
ter according to mRNA expression subtype with repre-
sentatives from all subtypes (Additional file 1d). Using
the chi-squared test to assess the association between
the six COCA clusters and clinical parameters, cluster 1
was associated with grade (p = 0.001; mostly grade 2 and
3), ER (p = 0.009; mostly ER-positive), PR (p = 0.042;
mostly PR-negative) and TP53 status (p = 0.018; mostly
wild-type) (Additional files 1e and 7).
COCA cluster 2
COCA cluster 2 was most strongly correlated to the lu-
minal B subtype (r = 0.82; corresponding to 93.2% of the
tumors in the cluster), PARADIGM 1 cluster (r = 0.55;
high activation of the ER-alpha network and targets of
C-MYC transcriptional activation, low activation of
JUN/FOS signaling and targets of C-MYC transcrip-
tional repression) and miRNA 1 cluster (r = 0.32)
(Table 1). Furthermore, cluster 2 was significantly associ-
ated with grade (p = 0.018; grade 2 and 3), HER2 (p =
0.023; almost exclusively HER2-negative), ER (p < 0.001;
all positive) and PR status (p = 0.025; mostly positive)
(Additional files 1e and 7).
COCA cluster 3
Overall, tumors in COCA cluster 3, which represented
the basal subgroup (93.5% of the tumors; correlation
with the basal-like subtype = 0.76) were the most
strongly correlated. COCA cluster 3 was most strongly
correlated to the IntClust 10 group (r = 0.83), which has
previously been associated with younger age at diagno-
sis, high-grade and large tumors [3]. The tumors in
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cluster 3 were also strongly correlated to the PARA-
DIGM 2 cluster (r = 0.71), the basal RPPA subtype (r =
0.67) and the miRNA 3 cluster (r = 0.40) (Table 1). Fur-
thermore, cluster 3 was associated with grade (p <
0.001; all except one tumor were of the highest
grade), ER (p < 0.001; mostly negative), PR (p < 0.001;
mostly negative) and TP53 status (p < 0.001; all except
for two tumors were mutated) (Additional files 1e
and 7). All tumors in cluster 3 were HER2-negative
and this cluster also represented the largest propor-
tion of patients diagnosed at a younger age (<50 years)
(Additional file 7).
Fig. 2 Cluster-of-clusters analysis (COCA) identifies six major groups based on seven molecular input levels. Consensus clustering was used to
cluster 419 primary breast cancers in the Oslo2 study. The six resulting COCA clusters are numbered and the corresponding PAM50 subtype
indicated (top). Heatmap representation of the subtypes/clusters independently defined: PAM50 mRNA subtypes, reverse-phase protein array
(RPPA) expression subtypes, complex arm aberration index (CAAI) subtypes based on copy numbers, miRNA clusters, metabolic clusters, pathway
recognition algorithm using data integration on genomic models (PARADIGM) clusters and integrated clusters (IntClust). Colored bar indicates
membership of a subtype/cluster type, white indicates no membership to a given subtype and gray represents data not available (NA). The rows
in the heatmap are ordered according to clustering. Clinical annotation of the tumors is shown (bottom). HER2 human epidermal growth factor
receptor 2, Lum luminal, Mut mutant, WT wild-type
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COCA cluster 4
COCA cluster 4 exclusively comprised tumors of the
luminal A expression subtype, and correspondingly
this level was the most strongly correlated (r = 0.63).
Cluster 4 tumors were also correlated with miRNA
cluster 1 (r = 0.45) and with the RPPA luminal group
(r = 0.30; Table 1). Furthermore, this cluster was sig-
nificantly associated with grade (p < 0.001; mostly
grade 1 and 2), ER (p < 0.001; all positive), PR (p =
0.003; mostly positive), HER2 (p = 0.007; all except
one were negative) and TP53 status (p = 0.001; mostly
wild-type) (Additional files 1e and 7). With only
12.7% TP53 mutated tumors, this was the cluster with
the lowest frequency of TP53 mutations.
COCA cluster 5
COCA cluster 5 was most strongly correlated with
miRNA cluster 4 (r = 0.55), and the normal-like subtype
(r = 0.43; 43.1% of the tumors). Tumors of the basal-like
and luminal subtypes were also present, but notably, this
cluster contained a substantial subgroup of tumors
(34.5%) that were lacking PAM50 subtype classification
(and thus also IntClust and PARADIGM classifications).
Cluster 5 was significantly associated with histology (p =
0.017; Additional file 1e); this cluster was the most histo-
logically diverse cluster with the lowest frequency of
ductal carcinomas (62.7%) compared to the other clus-
ters and with the highest frequency of lobular (17.6%)
and ductal carcinoma in situ (DCIS) samples (11.8%)
(Additional file 7).
COCA cluster 6
COCA cluster 6 was the smallest cluster in size, with
only 35 tumors. These were mainly of the HER2-
enriched subtype (r = 0.73; 82.9% of the tumors), but also
including a few tumors from the basal-like, luminal B
and normal-like subtypes (Additional file 1d). Cluster 6
was also highly correlated with the IntClust 5 group (r =
0.69) which correspondingly represented tumors with
amplification of the ERBB2 gene in the original METAB-
RIC cohort [3], and to the RPPA HER2 subtype (r =
0.68). Furthermore, this cluster was associated with
grade (p < 0.001; mostly grade 3), ER, PR, HER2 and
TP53 (all p < 0.001) and PIK3CA status (p = 0.049)
(Additional files 1e and 7). Tumors in this cluster
were mainly high grade (84.6% grade 3), and this
cluster had the second highest frequency of TP53
mutations (69.2%) after the basal-like cluster 3. In
contrast, it was the cluster with the lowest frequency
of PIK3CA mutations (8.0%).
Contribution from the different molecular levels in
varying degrees
Figure 3 summarizes the correlation values between all
molecular levels and all six COCA clusters, showing the
contribution from each level. All the five PAM50 sub-
types and the four miRNA clusters had maximum corre-
lations that were above 0.3. Three of the five RPPA
subtypes (basal, HER2 and luminal) also showed high
maximums, and the same was true for two out of seven
PARADIGM clusters (cluster 1 and 2) and two out of
ten IntClusts (IntClusts 5 and 10). Neither of the three
CAAI groups, nor the three metabolic clusters showed
high correlations to any COCA cluster.
miRNA expression split the luminal A tumors
Interestingly, the luminal A tumors were split into
COCA cluster 1 and COCA cluster 4. This was most
evidently due to different miRNA cluster assignment
(Fig. 2). Therefore, miRNA differential expression was
calculated between the luminal A tumors in COCA clus-
ter 1 versus COCA cluster 4. Altogether, 71 miRNAs
were identified as differentially expressed (Additional file
1f ). To study the functional role of these miRNAs that
were differentially expressed between luminal A tumors
in COCA cluster 1 and COCA cluster 4, we performed
miRNA gain-of function studies in the ER-positive cell
line MCF-7. Proliferation, apoptosis, viability, phosphor-
ylated AKT (p-AKT) levels and ER levels were used as
endpoints (Additional file 8).
Of the 71 miRNAs assessed, 13 miRNAs had func-
tional effects when overexpressed in MCF-7: miR-23a*,
miR-33b, miR-33b*, miR-125a-3p, miR-452, miR-492,
miR-494, miR-526b, miR-582-5p, miR-654-5p, miR-765,
miR-934 and miR-1226*. Of these, mir-33b and miR-
582-5p were higher expressed in COCA cluster 4, while
Table 1 Top five molecular subtype levels ranked according to correlation to each COCA cluster
COCA cluster 1 COCA cluster 2 COCA cluster 3 COCA cluster 4 COCA cluster 5 COCA cluster 6
miRNA2 (0.80) PAM50 - LumB (0.82) IntClust10 (0.83) PAM50 - LumA (0.63) miRNA4 (0.55) PAM50 - HER2 (0.73)
PAM50 - LumA (0.23) PARADIGM1 (0.55) PAM50 - Basal (0.76) miRNA1 (0.45) PAM50 - Normal (0.43) IntClust5 (0.69)
PARADIGM6 (0.15) miRNA1 (0.32) PARADIGM2 (0.71) RPPA - Luminal (0.30) RPPA - ReacI (0.25) RPPA - HER2 (0.68)
IntClust4 (0.12) IntClust1 (0.28) RPPA - Basal (0.67) IntClust3 (0.29) Metabolic2 (0.15) CAAI3 (0.28)
PARADIGM5 (0.12) IntClust9 (0.27) miRNA3 (0.40) PARADIGM4 (0.27) miRNA3 (0.13) PARADIGM2 (0.28)
Values in parentheses are the Pearson correlation values. Correlation ≥0.3 (p < 0.001 for all) is indicated in bold font. COCA cluster-of-clusters analysis, LumA luminal
A, PARADIGM pathway recognition algorithm using data integration on genomic model, IntClust integrated clusters, RPPA reverse-phase protein array, CAAI complex arm
aberration index
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the rest were higher expressed in COCA cluster 1. Inter-
estingly, miR-1226* had several tumor-suppressor fea-
tures: overexpression led to reduced cell viability and
proliferation and increased apoptosis. Furthermore,
overexpression of miR-1226* led to reduced ER and p-
AKT. Overexpression of miR-452 and miR-526b led to
both reduced proliferation and p-AKT.
In order to further couple the 71 differentially
expressed miRNAs to biological function, correlation
between these and the mRNA expression of all genes
was calculated. Retaining the genes with the highest
absolute correlation (Spearman rank correlation >
|0.4|) resulted in a list of 1808 unique genes
(Additional file 1g). Further, we tested which of these
1808 genes were significantly differentially expressed
between luminal A tumors in COCA cluster 1 versus
COCA cluster 4 and identified 1323 genes (Benja-
mini-Hochberg corrected p-value <0.05), of which 473
genes were upregulated in luminal A tumors in
COCA cluster 1 (compared to luminal A tumors in
COCA cluster 4) and 850 genes were upregulated in
COCA cluster 4 (compared to luminal A tumors in
COCA cluster 1; Additional file 1g). Finally, IPA was
used to test for enrichment of pathways within the
two lists of genes upregulated in luminal A tumors in
the respective COCA clusters. After correcting for
multiple testing, no pathways were enriched among
the genes upregulated in luminal A tumors in COCA
cluster 1. In the luminal A tumors in COCA cluster
4, 15 pathways were enriched among the upregulated
genes (Benjamini-Hochberg-corrected p-value <0.05
(Fisher’s exact test); Additional file 9). The top five
most significantly enriched pathways included mito-
chondrial dysfunction, EIF2 signaling, oxidative phos-
phorylation, protein ubiquitination pathway, and
androgen signaling (Additional file 1h).
Fig. 3 Correlation between cluster-of-clusters analysis (COCA) clusters and molecular input levels. Pearson correlation coefficient (y-axis) calculated
between each molecular subtype level and each COCA cluster (x-axis) by coding membership to a cluster as 1 and 0 otherwise. Each panel
represents one molecular input level to the COCA analysis. RPPA reverse-phase protein array, CAAI complex arm aberration index, PARADIGM
pathway recognition algorithm using data integration on genomic models, IntClust integrated clusters, HER2 human epidermal growth factor
receptor 2, Lum luminal
Aure et al. Breast Cancer Research  (2017) 19:44 Page 12 of 18
Further, using chi-squared tests to assess if the luminal
A samples in the two clusters were also different with
respect to the other COCA input levels, both PARA-
DIGM clusters and RPPA subtype distributions were sta-
tistically significant (p-value <0.001 and p-value = 0.002,
respectively). The largest proportion of luminal A sam-
ples in COCA cluster 1 (36%) belonged to the PARA-
DIGM 4 cluster, while the largest in COCA cluster 4
belonged to the PARADIGM 3 cluster (29%). The most
striking difference in pathway activity levels between
these two PARADIGM clusters was the lower activation
of JUN/FOS-associated pathways in PARADIGM 3 (lu-
minal A tumors in COCA cluster 4) and higher activa-
tion in PARADIGM 4 (luminal A tumors in COCA
cluster 1; Additional file 5).
Although all tumors were classified as luminal A
based on mRNA expression, the RPPA subtype distri-
bution was different; among the tumors with RPPA
classification most of the COCA cluster 1 tumors
were classified as reactive I (47%) and reactive II
(26%), while most of the COCA cluster 4 tumors
were classified as luminal (71%) (note, only 34% of
the luminal A tumors in COCA clusters 1 and 4 were
assigned an RPPA subtype).
To further investigate the RPPA subtype-defined
differences between the luminal A samples, t tests
were used to assess the difference in protein expres-
sion. Of 148 proteins (antibodies) tested, 6 were
statistically significant (Benjamini-Hochberg adjusted
p-value <0.05): cleaved Caspase 9, 53BP1, AMPK-
alpha, GATA3, Rad51, and p90RSK (phosphorylated
at T359 and S363) (Additional file 10).
To assess potential interactions between these six
proteins and the 71 differentially expressed miRNAs
between luminal A tumors in COCA cluster 1 and 4, a
list of in silico predicted target genes of the 71 miRNAs
were obtained and overlaid with the 6 proteins. Five of
the six proteins were predicted to be targets of at
least one of the differentially expressed miRNAs
resulting in a list of ten potential miRNA-protein in-
teractions (Additional file 1i). Correlation analysis be-
tween miRNA and protein expression showed that of
the ten potential interactions, the presence of both
positive and negative correlation suggests the poten-
tial for both inhibitory and stimulating relationships
between these miRNAs and proteins.
There was no statistically significant difference in
clinicopathological parameters between luminal A
tumors in COCA cluster 1 compared to COCA clus-
ter 4 (p-value >0.05, chi-squared association tests).
Furthermore, there was no statistically significant dif-
ference in tumor percentage, or in correlation with
the PAM50 luminal A centroid or with the next near-
est subtype (data not shown).
Prognostic differences between luminal A tumors
As the Oslo2 cohort has been established relatively
recently, extensive follow-up data are not yet available.
To investigate the prognostic potential of the 71 miR-
NAs distinguishing the two groups of luminal A tumors,
luminal A tumors from four other datasets with available
miRNA expression and long-term follow up were
assessed; METABRIC (n = 447), TCGA (n = 230), the
Danish Breast Cancer Cooperative Group (DBCG)
(n = 33) and the Oslo Micrometastasis cohort
(Micma) (n = 29). Of the 71 miRNAs in the signa-
ture, 68 miRNAs were available in the METABRIC
cohort and 56 miRNAs were available in the three
latter datasets.
Clustering the luminal A tumors in each of the data-
sets on the expression of these miRNAs revealed two
main clusters in each cohort (Fig. 4). A log-rank test was
used to assess if the survival curves were different in the
two groups. Indeed, in TCGA and the DBCG the split in
the luminal A tumors based on the expression of the 56
miRNAs was related to differences in outcome (overall
survival and freedom from any recurrence, log-rank p-
values 0.003 and 0.045, respectively: the DBCG log-rank
p-value was adjusted for radiation therapy and lymph
node status and the adjusted hazard ratio was 2.52 (95%
CI 1.02–6.24)). In the METABRIC cohort there was a
trend towards differences in prognosis between the
two clusters for overall survival, but the log-rank test
was not significant after adjusting for hospital (p =
0.090 after stratification). There was no prognostic
difference in the Micma cohort, possibly due to the
small sample size (p-value = 0.113).
RPPA subtypes of the TCGA tumors [9] confirmed the
findings from Oslo2 that the constitution of the luminal
A tumors split according to miRNA were different with
respect to protein-defined subtypes; TCGA tumors in
the cluster with worse prognosis represented 43%
luminal tumors (scored as luminal A or luminal A/B
RPPA subtype), 3% reactive I tumors and 5% reactive II
tumors (Additional file 1j). On the other hand, TCGA
tumors in the cluster with a better prognosis represented
22% luminal tumors, 12% reactive I tumors and 3%
reactive II tumors. Thus, the cluster with a better prog-
nosis represented a larger proportion of reactive tumors
and fewer luminal tumors compared to the cluster with
a poorer prognosis. According to these findings the
luminal A tumors in COCA cluster 1 may have a better
prognosis than those in COCA cluster 4. Furthermore,
of the six proteins that were differentially expressed
between luminal A tumors in Oslo2 (Additional file 10),
four were present in the TCGA data. Three of these,
GATA3, RPS6KA1 and PRKAA1 followed the same
trend with respect to different expression (high/low) in
TCGA, but only RPS6KA1 was statistically significantly
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differentially expressed (t test p-value = 0.01; GATA3 p-
value = 0.08 and PRKAA1 p-value = 0.14).
Discussion
The input to the COCA analysis was seven different
classifications of breast tumors; the PAM50 subtype,
RPPA subtype, metabolic cluster, miRNA cluster, CAAI,
PARADIGM and IntClust. The five former were single-
molecular-level classifications, while the IntClust and
PARADIGM classifications were based on the combined
analysis of copy number and expression data in two dif-
ferent ways; iClustering assigned each tumor to one of
ten IntClusts derived from the METABRIC cohort, while
PARADIGM identified patient clusters based on in-
ferred pathway activity levels. The distance in the
consensus clustering method was normalized so that
the different layers would be comparable in terms of
number of missing values associated with each layer.
Furthermore, a strength of the current work is the
processing of the tumors where cutting and blending
the tissue before dividing it into DNA, RNA and pro-
tein isolation ensured representative and comparable
molecular data.
We identified six COCA clusters in our analysis. Con-
sidering the ranking of the molecular levels based on
correlation with the COCA clusters (Table 1), PAM50
subtypes and miRNA clusters were the most strongly
correlated; all of the five subtypes and four miRNA clus-
ters were present among the strongest correlations. The
PAM50 subtypes have been recognized as a robust clas-
sifier [9]. miRNA expression has previously been associ-
ated with both gene expression-based subtypes and with
clinical parameters [45, 46], but subtypes have not yet
been “formally” established based on miRNA expression.
Interestingly, on ranking all the molecular levels, COCA
clusters 1 and 5 were most strongly correlated with
miRNA clusters 2 and 4, respectively, suggesting an im-
portant role for miRNAs in the separation of breast
tumors.
In the TCGA breast study [9], seven miRNA
expression-defined subtypes were identified by consen-
sus non-negative matrix factorization clustering. Except
for two of the clusters, each of the clusters was a mix-
ture of the PAM50-defined subtypes. As the four identi-
fied consensus clusters mainly recapitulated the PAM50
subtypes, the miRNA clusters were not given a dominant
role in the TCGA study. Importantly, this particular
study contained very few normal-like samples (1%), and
thus the tumor distribution was different from the Oslo2
cohort consisting of 11% normal-like tumors. Similarly
Fig. 4 miRNA expression separates luminal A tumors into clusters with different outcomes. Top panel Luminal A tumors in The Cancer Genome
Atlas (TCGA), Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), Danish Breast Cancer Cooperative Group (DBCG) and the
Oslo Micrometastasis cohort (Micma) breast cancer cohorts were clustered based on the expression of selected miRNAs using Pearson correlation
and complete linkage (patients in columns and miRNAs in rows). Bottom panel Kaplan-Meier survival curves for the red and blue clusters in the top
panel. The p-values are from log-rank tests (METABRIC p-value was adjusted for hospital site and DBCG p-value was adjusted for radiation therapy
and lymph node status). Dashed lines indicate confidence intervals for the survival curves
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as in the TCGA study, the basal-like COCA cluster 3
had the most distinct signature with the strongest asso-
ciations with several levels; IntClust 10, PAM50 basal
subtype, PARADIGM cluster 2, RPPA basal subtype, and
miRNA cluster 3 were all strongly correlated with this
cluster.
There was also correlation between the COCA clusters
and some of the RPPA subtypes, PARADIGM clusters
and IntClusts; however, neither the metabolic clusters
nor the CAAI subtypes were strongly correlated with
any of the COCA clusters, suggesting that grouping
based on metabolic clusters and complexity of DNA re-
arrangements are less strongly associated with the mo-
lecular subtypes driven by the other platforms.
Luminal A tumors represent the most frequent breast
cancer subtype (approximately 40% of all cases).
Although considered to have the best prognosis, the
luminal A subtype is also characterized as the most
heterogeneous group, both clinically and molecularly
[9, 47]. Some patients with this disease subtype suffer
from relapse and may benefit from adjuvant treat-
ment, while others risk unnecessary over-treatment
with adverse side effects. Furthermore, survival curves
for patients with luminal A tumors suggest that the
risk of delayed local relapse and/or distant metastasis
persists over long time periods compared to other
subtypes [48].
Heterogeneity at the molecular level was found for lu-
minal A tumors in terms of mRNA expression, mutation
spectrum and copy number changes in the TCGA breast
cancer study [9]. In the METABRIC study, which identi-
fied ten integrative clusters across breast cancers, lu-
minal A tumors were separated mainly into three
distinct subgroups which were found to be driven by
specific genomic aberrations [3]. Ciriello et al. [47] ana-
lyzed copy number and mutation profiles in luminal A
tumors and identified four major subtypes with distinct
alterations and clinical outcomes.
Being able to distinguish subgroups of luminal A tu-
mors is an important task and may potentially improve
the choice of therapeutic approaches and prediction of
clinical outcomes. In this respect, the split of the Oslo2
luminal A samples into COCA clusters 1 and 4 may sug-
gest a novel refinement of this group. It was interesting
to see that the two luminal A clusters were associated
with different miRNA clusters and that overexpression
of 13 of the 71 differentially expressed miRNAs in the
luminal cell line MCF-7 directly showed functional
effects that are important for cancer cell survival. The
putative tumor-suppressor miRNA miR-1226*, which
was more highly expressed in COCA cluster 1 and for
which overexpression resulted in both decreased prolif-
eration, cell viability, ER and p-AKT levels, and in-
creased apoptosis, has previously been found to target
and downregulate expression of the MUC1 oncoprotein
and induce cell death [49].
Although long-term follow up of the Oslo2 patients is
not yet available, it was intriguing to see that in patients
from four other cohorts, luminal A tumors formed two
separate clusters when clustered on the same miRNAs
differentially expressed in Oslo2. Furthermore, there was
a prognostic difference between the patient clusters in
the TCGA and DBCG cohorts. From the other molecu-
lar differences identified between those clusters, it may
seem that the tumors in COCA cluster 4 are more
“core” luminal, as they were more frequently assigned to
the luminal protein-based subtype and with higher pro-
tein expression of the luminal marker GATA3 [50].
The majority of the luminal A tumors belonging to
COCA cluster 1 were of the RPPA-defined reactive I and
II subgroups, which were characterized as being highly
differentiated tumors with high expression of stromal pro-
teins due to high numbers of stromal cells, lower levels of
GATA3 protein compared to other tumors classified as lu-
minal A/B from gene expression and with a favorable clin-
ical outcome [39]. This difference in association between
the RPPA subtype and the luminal A clusters separated by
miRNA expression was also seen in the TCGA cohort in
which RPPA subtypes were available. Coupling this to out-
come data, it seems that the cluster with more tumors
classified as the reactive subtype is associated with a better
prognosis. The 71 miRNA signatures would need further
development to serve as a diagnostic test for patients with
luminal A tumors. miRNA-based tests may be beneficial
as miRNA molecules are short and relatively stable [51]
and can be successfully applied on, for example, formalin-
fixed paraffin-embedded tissue. Further studies for better
understanding of the underlying biology and the possible
role of miRNAs as markers to separate luminal tumors
with different clinical outcome or response to therapy is
needed and will be exciting to follow up.
Conclusions
In summary, the six integrated subtypes identified in the
current study underline the heterogeneity of breast can-
cer, but also show that finer subdivisions of subtypes
might not be a second-order effect, but might be as
strong as the established taxonomies. We were able to
validate the split of the luminal A tumors found in Oslo2
based on miRNA expression in four other cohorts and
in two of them, TCGA and DBCG, the resulting clusters
showed differences in disease outcome. Increasing the
knowledge of the heterogeneity of the luminal A subtype
of breast cancer revealing more detailed subcategoriza-
tions may add to informing therapeutic choices, evi-
dently bringing improved treatment for this largest
subgroup of breast cancer.
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